[The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Recent breakthrough in cancer immunotherapy employing immune checkpoint inhibitors(ICI)has evolved into number of clinical trials with antibodies against PD-1, PD-L1, and CTLA-4 for patients with squamous cell carcinoma of head and neck (SCCHN). The development of ICI in SCCHN initiated in the recurrent and metastatic setting. CheckMate141 supports nivolumab as a standard therapy for patients with platinum-refractory recurrent and metastatic-SCCHN. KEYNOTE-048 testing pembrolizumab demonstrated future practice-changing data in platinum sensitive recurrent and metastatic-SCCHN. ICI may open the door to a new era of tailor-made medicine in treatment of recurrent and metastatic-SCCHN, based on tumor burden, clinical stability, and PD-L1 status. Furthermore, ICI in combination with concurrent cisplatin based chemoradiotherapy has been investigated for locoregionally advanced disease.